200-028 - Steno2tech Study. Comparing CGM and BGM in Adults with inadequately controlled insulin treated T2D
Online Course
•
Dexcom (UK) Distribution
About the CPD course
Join Dr Nanna Lind; lead author of the Steno2tech Study; as she discusses important outcomes of this research evaluating long-term effects of continuous glucose monitoring (CGM) versus capillary blood glucose monitoring (CBG) in adults living with insulin-treated type 2 diabetes (T2D) currently not achieving targets. This study found that CGM-correlated improvements were sustained over the long term; noting the benefits at six months were sustained at 12-months. In addition; researchers noted that CGM overcomes the limitations of traditional blood glucose monitoring–which can be painful; inconvenient; and fail to capture a complete glycaemic picture; given the intermittent nature of CBG.
At Dexcom, we believe that with diabetes, knowledge is power, we’ve spent the last 20 years innovating and developing simpler and better ways for people with type 1 diabetes to measure, track and manage their diabetes. When Dexcom was established the only way to measure glucose levels was to fingerstick, it gave us a snapshot not a story which made it difficult to understand our glucose levels and trends over time or feel in control of our diabetes. Since then, we’ve launched the world’s first real-time CGM system and helped to eliminate more than 11 billion fingersticks.
